Drugs / LMT503
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05659953 | Apr → Oct 2025 overdue | Crohn disease, ulcerative colitis | Lmito Therapeutics Inc. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LMT503 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05659953 ↗ |
| Route | Oral | “Subjects will receive one of several different oral doses of LMT503 once daily” NCT05659953 ↗ |